drugset / Trial / NCT00520806

Efficacy and Safety of Relaxin for the Treatment of Acute Heart Failure

NCT00520806

RandomizedParallel-groupQuadruple-blindTreatment

Summary

Different doses of relaxin will be compared to placebo to determine efficacy and safety for the treatment of patients hospitalized with acute heart failure

Timeline

Start
2007-10
Primary completion
2012-09
Completion
2012-09

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Relaxin Protein / enzyme biologic 30 ug/kg Intravenous